Navigation Links
Inhibition of CDK4 might promote lymphoma development and progression

COLUMBUS, Ohio Anticancer agents that inhibit tumor growth by targeting a regulatory protein called CDK4 might actually promote the development and progression of certain B-cell lymphomas, according to a new study led by researchers at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).

The study indicates that inhibiting CDK4, a regulator of the cell cycle, promotes genetic instability and the development or progression of B-cell lymphomas that are driven by the MYC oncogene.

The research suggests that CDK4 inhibitors, which are now in clinical testing, should be used cautiously, particularly in patients with B-cell lymphomas. The findings also raise the possibility that these inhibitors work through off-target effects and require further investigation.

The study is published in The Journal of Clinical Investigation.

"Anti-CDK4 strategies are being widely tested as broad-spectrum anticancer therapies," says study leader Xianghong Zou, PhD, assistant professor of medicine and a member of the OSUCCC James Molecular Carcinogenesis and Chemoprevention Program. Zou's collaborators on the research included John Cleveland, PhD, professor and chair of cancer biology at The Scripps Research Institute.

"Our findings indicate that anti-CDK4 strategies must be carefully tailored because they might have unexpected lymphoma-promoting effects," Zou says.

"It was quite striking," he adds. "Silencing Cdk4 in our mouse model and in human B-cell lymphoma cells had the opposite effect of small-molecule inhibitors that are touted as selective inhibitors of CDK4 and CDK6," he says.

"Given that these agents have undergone limited profiling, it might be that these agents inhibit kinases other than CDK4, and that in lymphoma cells they promote critical factors that support cell growth and survival."

For this study, Zou and his colleagues used a mouse model of MYC-driven B-cell lymphoma they had developed earlier, and human cell lines of Burkitt and other non-Hodgkin lymphomas.

Key technical findings include:

  • Although CDK4 functions as an oncogene in breast and other cancers, loss of CDK4 can greatly promote cancer onset and growth in a model of MYC-driven B-cell lymphoma and in human B-cell lymphoma cells;

  • The lymphoma-promoting effects of the experimental CDK4 deficiency were associated with dysregulation of a gene pathway that leads to genomic instability;

  • CDK4 deficiency leads to lymphomas with major genomic alterations that are associated with the dysregulation of genes that are known to promote cancer.

Contact: Darrell E. Ward
Ohio State University Wexner Medical Center

Related medicine news :

1. Specific inhibition of autophagy may represent a new concept for treatment of kidney cancer
2. Treating drug resistant cancer through targeted inhibition of sphingosine kinase
3. Novel test identifies patients most likely to benefit from ALK inhibition therapy
4. Neurological Wellness Center's Novel Neuro-Inflammation Inhibition Procedure that Induces Rapid Recovery from Alzheimer's, Stroke and Brain Injury is Now Being Taught in a Newly Released Video
5. Epoxide hydrolase inhibition and Thiazolidinediones: A therapy for cardiometabolic syndrome
6. New STELARA data show inhibition of joint destruction in active psoriatic arthritis
7. Inhibition of oral biofilm and cell-cell communication using natural-products derivatives
8. New Stool Test Might Aid in Early Detection of Colon Cancer
9. Depo-Provera Birth Control Might Raise Breast Cancer Risk
10. Brain Falters Near End of Life, but Games, Puzzles Might Slow Decline
11. Infection Might Raise Blood Clot Risk for Older Adults: Study
Post Your Comments:
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
Breaking Medicine Technology: